TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Vicore Pharma AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
47
|
255
|
287 |
| Financial expenses |
0
|
0
|
42 |
| Earnings before taxes |
-25,400
|
-24,815
|
-28,539 |
| EBITDA |
-24,309
|
-24,829
|
-28,344 |
| Total assets |
10,306
|
10,999
|
18,284 |
| Current assets |
10,212
|
9,687
|
17,290 |
| Current liabilities |
6,290
|
4,417
|
8,935 |
| Equity capital |
3,943
|
6,493
|
9,325 |
| - share capital |
9
|
9
|
10 |
| Employees (average) |
19
|
16
|
12 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
38.3%
|
59.0%
|
51.0% |
| Turnover per employee |
2
|
16
|
24 |
| Profit as a percentage of turnover |
-54042.6%
|
-9731.4%
|
-9943.9% |
| Return on assets (ROA) |
-246.5%
|
-225.6%
|
-155.9% |
| Current ratio |
162.4%
|
219.3%
|
193.5% |
| Return on equity (ROE) |
-644.2%
|
-382.2%
|
-306.0% |
| Change turnover |
-209
|
-9
|
-4 |
| Change turnover % |
-82%
|
-3%
|
-1% |
| Chg. No. of employees |
3
|
4
|
3 |
| Chg. No. of employees % |
19%
|
33%
|
33% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.